Olema Pharmaceuticals (NASDAQ:OLMA) Insider Naseem Zojwalla Sells 99,509 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Naseem Zojwalla sold 99,509 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $27.66, for a total value of $2,752,418.94. Following the sale, the insider directly owned 4,488 shares in the company, valued at $124,138.08. This trade represents a 95.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Naseem Zojwalla also recently made the following trade(s):

• On Friday, December 19th, Naseem Zojwalla sold 70,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.20, for a total value of $1,974,000.00.
• On Monday, December 22nd, Naseem Zojwalla sold 100,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $28.04, for a total value of $2,804,000.00.

Olema Pharmaceuticals Stock Down 1.8%

OLMA opened at $27.67 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -14.80 and a beta of 1.87. Olema Pharmaceuticals, Inc. has a one year low of $2.86 and a one year high of $36.26. The business’s fifty day moving average is $18.58 and its two-hundred day moving average is $10.56.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). Analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Paradigm Biocapital Advisors LP increased its stake in Olema Pharmaceuticals by 0.4% in the third quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock valued at $66,515,000 after purchasing an additional 30,000 shares during the last quarter. Deep Track Capital LP grew its holdings in Olema Pharmaceuticals by 0.8% in the 3rd quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock valued at $33,973,000 after buying an additional 27,339 shares during the period. MPM Bioimpact LLC increased its stake in shares of Olema Pharmaceuticals by 0.6% during the 1st quarter. MPM Bioimpact LLC now owns 2,930,446 shares of the company’s stock valued at $11,018,000 after acquiring an additional 17,896 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of Olema Pharmaceuticals by 8.9% during the 1st quarter. Woodline Partners LP now owns 1,477,907 shares of the company’s stock worth $5,557,000 after acquiring an additional 120,428 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Olema Pharmaceuticals by 22.4% in the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after acquiring an additional 242,997 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. HC Wainwright increased their price target on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. Guggenheim started coverage on Olema Pharmaceuticals in a research report on Wednesday, October 8th. They set a “buy” rating and a $20.00 price target for the company. JPMorgan Chase & Co. upped their price objective on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, Oppenheimer increased their price objective on Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Olema Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $40.50.

Key Stores Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Negative Sentiment: Naseem Zojwalla sold 99,509 shares on Dec. 23 at an average $27.66 for ~$2.75M; holding afterward fell to 4,488 shares (a ~95.7% reduction). SEC Form 4 – Zojwalla sale 12/23/2025
• Negative Sentiment: Naseem Zojwalla sold 70,000 shares on Dec. 19 at an average $28.20 for ~$1.97M; his reported direct holding dropped ~40% after that trade. SEC Form 4 – Zojwalla sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla sold 100,000 shares on Dec. 22 at an average $28.04 for ~$2.80M; his combined transactions over the week materially reduced his stake. SEC Form 4 – Zojwalla sale 12/22/2025
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at an average $30.46 for ~$1.55M, trimming his position by ~8.5%. SEC Form 4 – Myles sale 12/19/2025
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at an average $29.73 for ~$7.87M — a very large director-level disposal that can amplify market concern. SEC Form 4 – Clark sale 12/19/2025

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.